Identifying high value global in-licensing targets in the RNA/ASO space
Challenge
A top pharmaceutical company sought to evaluate emerging approaches in intracellular delivery and tissue-specific targeting of RNA/ASO molecules
The client needed to understand corporate and venture fund investment patterns
Ultimately, the client wanted to inform an important acquisition
Approach
Conducted a comprehensive market evaluation of emerging RNA/ASO delivery technologies with a focus on GalNac targeting and other receptor-mediated approaches
Compared the assets using competitive grids and flagged differentiating features
Profiled licensing and partnership activity and identified unpartnered assets
Results
Our team produced a rapid-turnaround, comprehensive landscape evaluation including key challenges and potentially disruptive approaches
Our client used this analysis to inform a key partnership (>$225 MM)
